<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="8" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font9" size="8" family="SymbolMT" color="#000000"/>
<text top="42" left="56" width="181" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Breast Cancer Research Vol 8 No 6    Harris et al.<b>Breast Cancer Research</b></text>
<text top="758" left="56" width="45" height="7" font="font1" id="p1_t2" reading_order_no="74" segment_no="9" tag_type="text">Page 8 of 12</text>
<text top="768" left="56" width="120" height="6" font="font3" id="p1_t3" reading_order_no="75" segment_no="10" tag_type="text">(page number not for citation purposes)<i>et al.</i></text>
<text top="590" left="56" width="240" height="9" font="font4" id="p1_t4" reading_order_no="10" segment_no="6" tag_type="text">women and Caucasian women with p53 mutations as</text>
<text top="602" left="56" width="240" height="9" font="font4" id="p1_t5" reading_order_no="11" segment_no="6" tag_type="text">assessed by IHC (41% and 38%, respectively; P = 0.78) or<i>(page number not for citation purposes)</i></text>
<text top="614" left="56" width="166" height="9" font="font4" id="p1_t6" reading_order_no="12" segment_no="6" tag_type="text">by sequencing (32% and 26%, P = 0.48).</text>
<text top="637" left="56" width="57" height="10" font="font6" id="p1_t7" reading_order_no="13" segment_no="7" tag_type="title">Discussion</text>
<text top="649" left="56" width="240" height="9" font="font4" id="p1_t8" reading_order_no="14" segment_no="8" tag_type="text">We evaluated the relationship among tumor biomarkers, treat-<i>P </i></text>
<text top="661" left="56" width="240" height="9" font="font4" id="p1_t9" reading_order_no="15" segment_no="8" tag_type="text">ment response, and outcomes in a subset of patients with</text>
<text top="673" left="56" width="240" height="9" font="font4" id="p1_t10" reading_order_no="16" segment_no="8" tag_type="text">available tumor blocks who were enrolled in a large, prospec-</text>
<text top="684" left="56" width="240" height="9" font="font4" id="p1_t11" reading_order_no="17" segment_no="8" tag_type="text">tive, randomized trial of single-agent paclitaxel given as first-<i>P </i></text>
<text top="696" left="56" width="240" height="9" font="font4" id="p1_t12" reading_order_no="18" segment_no="8" tag_type="text">line or second-line therapy for metastatic breast cancer.</text>
<text top="708" left="56" width="240" height="9" font="font4" id="p1_t13" reading_order_no="19" segment_no="8" tag_type="text">Neither HER2 status nor p53 status significantly affected the<b>Discussion</b></text>
<text top="720" left="56" width="240" height="9" font="font4" id="p1_t14" reading_order_no="20" segment_no="8" tag_type="text">treatment response or TTF when HER2 over-expression was</text>
<text top="85" left="315" width="240" height="9" font="font4" id="p1_t15" reading_order_no="21" segment_no="1" tag_type="text">scored as 3+ on the HercepTest or FISH positive. Although</text>
<text top="97" left="315" width="240" height="9" font="font4" id="p1_t16" reading_order_no="22" segment_no="1" tag_type="text">p53 status and ER status were not predictive of a benefit from</text>
<text top="109" left="315" width="240" height="9" font="font4" id="p1_t17" reading_order_no="23" segment_no="1" tag_type="text">therapy, measured by response or TTF, they were both impor-</text>
<text top="120" left="315" width="240" height="9" font="font4" id="p1_t18" reading_order_no="24" segment_no="1" tag_type="text">tant variables in determining OS in this cohort. Thus, it appears</text>
<text top="132" left="315" width="241" height="9" font="font4" id="p1_t19" reading_order_no="25" segment_no="1" tag_type="text">that p53 and ER status behaved as prognostic factors in this</text>
<text top="144" left="315" width="240" height="9" font="font4" id="p1_t20" reading_order_no="26" segment_no="1" tag_type="text">study, but they did not add predictive value within the context</text>
<text top="156" left="315" width="240" height="9" font="font4" id="p1_t21" reading_order_no="27" segment_no="1" tag_type="text">of response to paclitaxel. Although not surprising, this obser-</text>
<text top="167" left="315" width="240" height="9" font="font4" id="p1_t22" reading_order_no="28" segment_no="1" tag_type="text">vation underlines the importance of separating response to</text>
<text top="179" left="315" width="240" height="9" font="font4" id="p1_t23" reading_order_no="29" segment_no="1" tag_type="text">therapy from the underlying biology, a distinction first made by</text>
<text top="191" left="315" width="240" height="9" font="font4" id="p1_t24" reading_order_no="30" segment_no="1" tag_type="text">McShane and coworkers [40]. In addition, our study provides</text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t25" reading_order_no="31" segment_no="1" tag_type="text">support for the use of classification systems that include ER,</text>
<text top="214" left="315" width="240" height="9" font="font4" id="p1_t26" reading_order_no="32" segment_no="1" tag_type="text">PR, and HER2 status, because the outcomes according to</text>
<text top="226" left="315" width="240" height="9" font="font4" id="p1_t27" reading_order_no="33" segment_no="1" tag_type="text">these biomarkers in our cohort are consistent with published</text>
<text top="238" left="315" width="240" height="9" font="font4" id="p1_t28" reading_order_no="34" segment_no="1" tag_type="text">data [30,34]. Furthermore, racial differences in the pattern of</text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t29" reading_order_no="35" segment_no="1" tag_type="text">tumor subtypes are also seen, a finding that translates into dif-</text>
<text top="261" left="315" width="196" height="9" font="font4" id="p1_t30" reading_order_no="36" segment_no="1" tag_type="text">ferences in survival, even in the metastatic setting.<a href="">40].</a> In addition, our study provides</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t31" reading_order_no="37" segment_no="3" tag_type="text">Other studies have examined response to taxanes based on</text>
<text top="297" left="315" width="240" height="9" font="font4" id="p1_t32" reading_order_no="38" segment_no="3" tag_type="text">HER2 status. Seidman and coworkers [16] reported a higher</text>
<text top="308" left="315" width="240" height="9" font="font4" id="p1_t33" reading_order_no="39" segment_no="3" tag_type="text">rate of response to paclitaxel in patients with HER2-positive</text>
<text top="320" left="315" width="240" height="9" font="font4" id="p1_t34" reading_order_no="40" segment_no="3" tag_type="text">tumors; however, this association was seen only when HER2<a href="">data [30,34]. Fur</a>thermore, racial differences in the pattern of</text>
<text top="332" left="315" width="241" height="9" font="font4" id="p1_t35" reading_order_no="41" segment_no="3" tag_type="text">status was assessed with the use of the 4D5 antibody, and not</text>
<text top="344" left="315" width="241" height="9" font="font4" id="p1_t36" reading_order_no="42" segment_no="3" tag_type="text">when a rabbit polyclonal antibody (pAb-1) was used to deter-</text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t37" reading_order_no="43" segment_no="3" tag_type="text">mine HER2 status. The authors reported a low level of agree-</text>
<text top="367" left="315" width="240" height="9" font="font4" id="p1_t38" reading_order_no="44" segment_no="3" tag_type="text">ment between the results of the 4D5 assay and an assay with<a href="">s [16] repor</a>ted a higher</text>
<text top="379" left="315" width="241" height="9" font="font4" id="p1_t39" reading_order_no="45" segment_no="3" tag_type="text">pAb-1. The monoclonal antibody CB11 and the polyclonal</text>
<text top="391" left="315" width="240" height="9" font="font4" id="p1_t40" reading_order_no="46" segment_no="3" tag_type="text">antibody used in the HercepTest are known to target different</text>
<text top="402" left="315" width="240" height="9" font="font4" id="p1_t41" reading_order_no="47" segment_no="3" tag_type="text">epitopes of HER2 and appear to vary in the specificity of their</text>
<text top="414" left="315" width="240" height="9" font="font4" id="p1_t42" reading_order_no="48" segment_no="3" tag_type="text">results. Therefore, in the present study we evaluated the cor-</text>
<text top="426" left="315" width="241" height="9" font="font4" id="p1_t43" reading_order_no="49" segment_no="3" tag_type="text">relation among three methods of measuring HER2 status that</text>
<text top="438" left="315" width="240" height="9" font="font4" id="p1_t44" reading_order_no="50" segment_no="3" tag_type="text">have been approved by the US Food and Drug Administration.</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t45" reading_order_no="51" segment_no="3" tag_type="text">We found that the results of the CB11 assay, the HercepTest,</text>
<text top="461" left="315" width="240" height="9" font="font4" id="p1_t46" reading_order_no="52" segment_no="3" tag_type="text">and FISH were reasonably concordant, with the highest level</text>
<text top="473" left="315" width="196" height="9" font="font4" id="p1_t47" reading_order_no="53" segment_no="3" tag_type="text">of agreement between the CB11 assay and FISH.</text>
<text top="496" left="315" width="240" height="9" font="font4" id="p1_t48" reading_order_no="54" segment_no="4" tag_type="text">No association was seen between the rate of response to</text>
<text top="508" left="315" width="240" height="9" font="font4" id="p1_t49" reading_order_no="55" segment_no="4" tag_type="text">paclitaxel and HER2 status as assessed by any method. In</text>
<text top="520" left="315" width="240" height="9" font="font4" id="p1_t50" reading_order_no="56" segment_no="4" tag_type="text">contrast to our findings, Konecny and coworkers [21] reported</text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t51" reading_order_no="57" segment_no="4" tag_type="text">a statistically significant increase in response rate to epirubicin</text>
<text top="543" left="315" width="240" height="9" font="font4" id="p1_t52" reading_order_no="58" segment_no="4" tag_type="text">and paclitaxel, but not to epirubicin and cyclophosphamide, in</text>
<text top="555" left="315" width="240" height="9" font="font4" id="p1_t53" reading_order_no="59" segment_no="4" tag_type="text">women with HER2-positive tumors, as assessed by FISH. One</text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t54" reading_order_no="60" segment_no="4" tag_type="text">possible explanation for these conflicting results is that the</text>
<text top="579" left="315" width="240" height="9" font="font4" id="p1_t55" reading_order_no="61" segment_no="4" tag_type="text">patient populations were not entirely comparable, because all</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t56" reading_order_no="62" segment_no="4" tag_type="text">patients in the study reported by Konecny and coworkers<a href="">s [21]</a> reported</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t57" reading_order_no="63" segment_no="4" tag_type="text">received treatment as first-line therapy, whereas in CALGB</text>
<text top="614" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="64" segment_no="4" tag_type="text">9342 paclitaxel was given as either first-line or second-line</text>
<text top="626" left="315" width="240" height="9" font="font4" id="p1_t59" reading_order_no="65" segment_no="4" tag_type="text">therapy for metastatic disease. In addition, the treatment regi-</text>
<text top="637" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="66" segment_no="4" tag_type="text">mens were not entirely comparable. There may be an advan-</text>
<text top="649" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="67" segment_no="4" tag_type="text">tage to combining an anthracycline with a taxane in women</text>
<text top="661" left="315" width="240" height="9" font="font4" id="p1_t62" reading_order_no="68" segment_no="4" tag_type="text">with HER2-positive tumors; if so, epirubicin plus paclitaxel may</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t63" reading_order_no="69" segment_no="4" tag_type="text">be a particularly effective regimen against HER2-positive</text>
<text top="684" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="70" segment_no="4" tag_type="text">breast cancer, whereas HER2 status may not influence the</text>
<text top="696" left="315" width="240" height="9" font="font4" id="p1_t65" reading_order_no="71" segment_no="4" tag_type="text">likelihood of a response to paclitaxel given alone. Furthermore,</text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t66" reading_order_no="72" segment_no="4" tag_type="text">FISH techniques differed between these studies and might</text>
<text top="720" left="315" width="240" height="9" font="font4" id="p1_t67" reading_order_no="73" segment_no="4" tag_type="text">have influenced the findings. Finally, our sample was relatively</text>
<text top="85" left="56" width="31" height="7" font="font7" id="p1_t68" reading_order_no="1" segment_no="2" tag_type="title">Figure 1</text>
<text top="506" left="56" width="235" height="7" font="font8" id="p1_t69" reading_order_no="3" segment_no="5" tag_type="text">Time to treatment failure and overall survival according to p53 status,</text>
<text top="506" left="56" width="114" height="7" font="font8" id="p1_t70" reading_order_no="2" segment_no="5" tag_type="text">as assessed by immunochemistry</text>
<text top="516" left="56" width="240" height="7" font="font1" id="p1_t71" reading_order_no="4" segment_no="5" tag_type="text">as assessed by immunochemistry. (a) Time to treatment failure and (b)</text>
<text top="525" left="56" width="235" height="7" font="font1" id="p1_t72" reading_order_no="5" segment_no="5" tag_type="text">overall survival. Patients were classified as p53 positive (solid line) or</text>
<text top="535" left="56" width="231" height="7" font="font1" id="p1_t73" reading_order_no="6" segment_no="5" tag_type="text">p53 negative (dashed line) as determined by immunochemistry with</text>
<text top="542" left="56" width="241" height="10" font="font1" id="p1_t74" reading_order_no="7" segment_no="5" tag_type="text">D07 antibody. A positive case is defined as ≥ 10% positive, localization<b>Figure 1</b></text>
<text top="554" left="56" width="241" height="7" font="font1" id="p1_t75" reading_order_no="8" segment_no="5" tag_type="text">of nuclear or nuclear and cytoplasmic, and intensity of stain weak, mod-</text>
<text top="563" left="56" width="154" height="7" font="font1" id="p1_t76" reading_order_no="9" segment_no="5" tag_type="text">erate, or intense. IHC, immunohistochemistry.</text>
</page>
</pdf2xml>
